Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Current Liabilities (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Total Current Liabilities for 7 consecutive years, with $246.7 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 16.27% to $246.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $246.7 million through Dec 2025, up 16.27% year-over-year, with the annual reading at $246.7 million for FY2025, 16.27% up from the prior year.
  • Total Current Liabilities hit $246.7 million in Q4 2025 for Immunocore Holdings, up from $170.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $266.2 million in Q3 2024 to a low of $82.5 million in Q4 2021.
  • Historically, Total Current Liabilities has averaged $170.4 million across 5 years, with a median of $170.1 million in 2025.
  • Biggest five-year swings in Total Current Liabilities: surged 52.63% in 2024 and later plummeted 36.02% in 2025.
  • Year by year, Total Current Liabilities stood at $82.5 million in 2021, then grew by 18.17% to $97.5 million in 2022, then soared by 42.65% to $139.0 million in 2023, then soared by 52.63% to $212.2 million in 2024, then grew by 16.27% to $246.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for IMCR at $246.7 million in Q4 2025, $170.4 million in Q3 2025, and $170.1 million in Q2 2025.